Garkavij M - Search Results

1

Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab')2 in patients with MUC1-positive non-small cell lung cancer.

Garkavij M, Samarzija M, Ewers SB, Jakopovic M, Tezak S, Tennvall J. Garkavij M, et al. Anticancer Res. 2005 Nov-Dec;25(6C):4663-71. Anticancer Res. 2005. PMID: 16334158 Clinical Trial.

2

Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin.

Wang Z, Garkavij M, Tennvall JG, Ohlsson T, Strand SE, Sjögren HO. Wang Z, et al. Among authors: garkavij m. Cancer. 2002 Feb 15;94(4 Suppl):1287-92. doi: 10.1002/cncr.10298. Cancer. 2002. PMID: 11877758 Free article.

3

Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats.

Wang Z, Garkavij M, Ohlsson T, Strand SE, Sjögren HO, Tennvall J. Wang Z, et al. Among authors: garkavij m. Cancer Biother Radiopharm. 2003 Jun;18(3):365-75. doi: 10.1089/108497803322285116. Cancer Biother Radiopharm. 2003. PMID: 12954123

4

Improving radioimmunotargeting of tumors: the impact of preloading unlabeled L6 monoclonal antibody on the biodistribution of 125I-L6 in rats.

Garkavij M, Tennvall J, Strand SE, Norrgren K, Nilsson R, Sjögren HO. Garkavij M, et al. J Nucl Biol Med (1991). 1994 Dec;38(4):594-600. J Nucl Biol Med (1991). 1994. PMID: 7786923

5

Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.

Tennvall J, Garkavij M, Chen J, Sjögren HO, Strand SE. Tennvall J, et al. Among authors: garkavij m. Cancer. 1997 Dec 15;80(12 Suppl):2411-8. Cancer. 1997. PMID: 9406691

6

Comparison of 125I- and (111)In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption.

Garkavij M, Tennvall J, Ohlsson T, Lindgren L, Hindorf C, Sjögren HO, Strand SE. Garkavij M, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3059s-3064s. Clin Cancer Res. 1999. PMID: 10541344

7

A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.

Lindén O, Kurkus J, Garkavij M, Cavallin-Ståhl E, Ljungberg M, Nilsson R, Ohlsson T, Sandberg B, Strand SE, Tennvall J. Lindén O, et al. Among authors: garkavij m. Cancer Biother Radiopharm. 2005 Aug;20(4):457-66. doi: 10.1089/cbr.2005.20.457. Cancer Biother Radiopharm. 2005. PMID: 16114994 Clinical Trial.

8

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wingårdh K, Strand SE, Tennvall J. Garkavij M, et al. Cancer. 2010 Feb 15;116(4 Suppl):1084-92. doi: 10.1002/cncr.24796. Cancer. 2010. PMID: 20127957 Free article.

9

Enhanced radioimmunotargeting of 125I-labeled L6-biotin monoclonal antibody (MAb) by combining preload of cold L6 MAb and subsequent immunoadsorption in rats.

Garkavij M, Tennvall J, Strand SE, Norrgren K, Lindgren L, Nilsson R, Sjögren HO. Garkavij M, et al. Cancer Res. 1995 Dec 1;55(23 Suppl):5874s-5880s. Cancer Res. 1995. PMID: 7493363

10

Improving radioimmonotargeting of tumors. Variation in the amount of L6 MAb administered, combined with an immunoadsorption system (ECIA).

Garkavij M, Tennvall J, Strand SE, Norrgren K, Nilsson R, Lindgren L, Sjögren HO. Garkavij M, et al. Acta Oncol. 1993;32(7-8):853-9. doi: 10.3109/02841869309096146. Acta Oncol. 1993. PMID: 8305236

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters